A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B Infectio

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 80

Inclusion Criteria

1. Male or female adults between 18 and 65 years of age, inclusive
2. Chronic HBV infection greater than or equal to 6 months (e.g., positive for serum HBsAg greater than or equal to 6 months)
3. Taking a commercially available nucleos(t)ide analogs for at Least 2 months prior to Screening, and
willing to remain on stable treatment for the duration of the study, unless they achieve nucleos(t)ide.
stopping criteria.
4. HBV DNA less than 100 IU/mL in blood at Screening
5. HBsAg at Screening:
a. Part B Cohort 1: greater than LLOO to 3000 IU/mL.
In Part B, optional Cohorts and expansion subjects/arm/cohort (including Cohort 1), the upper Limit of 3000 IU/mL may be removed based on emerging data.

Exclusion Criteria

1. Pregnant or nursing females
2. Male or female subjects of childbearing potential unwilling to comply with contraception requirements during the study
3. Fibroscan greater than or equal to 8.5 kPa within 1 year of Screening
4. History of and/or current decompensated Liver disease as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal variceal bleeding
5. Presence of Liver disease, not including chronic HBV infection, such as nonalcoholic steatohepatitis (NASH), alcohol-associated hepatitis, cholestatic Liver disease, other viral (e.g., HCV or HDV) or non-viral hepatitis that has the potential to impact interpretation of data. Exceptions to this criterion include fatty Liver without any signs of steatohepatitis or past HCV
infection that was successfully treated greater than or equal to 6 months prior to Screening.
6. Positive for HIV, HDV, or HCV infection at Screening
7. Received solid organ or bone marrow transplant
8. Chronic systemic immunosuppressive therapy (e.g., prednisone) within 1 month of Screening or require the use of during the study.
9. Prior or current history of hepatocellular carcinoma (HCC) or suspected HCC as evidenced by screening alpha-fetoprotein greater than or equal to 20 ng/mL
10. History of hypersensitivity to any of the components in the cavrotolimod formulation or severe reactions to injections
11. Screening Laboratory results as follows, or any other clinically significant abnormalities in screening Laboratory values that would render a subject unsuitable for inclusion:
a. Presence of anti-thyroid antibodies (anti-thyroid-stimulating hormone receptor ITSHRI, anti thyroglobulin ITGI, or anti- thyroid peroxidase [TPO])
b. Abnormal thyroid stimulating hormone (TSH)
c. ANA greater than 1160
d. ALT or aspartate aminotransferase (AST) greater than 2 upper Limit of normal (ULN)
e. Total bilirubin greater than 1.2 ULN, except for subjects with Gilbert's (normal direct bilirubin)
f. Serum albumin less than .5 g/dL
g. International normalized ratio (INR) greater than 1.2
h. Platelet count less than 140 K/mm3
i. Hemoglobin Less than 12.0 g/dL for males and <11.0 g/dL for females
j. Absolute neutrophil count less than 1000/mm3
k. Estimated glomerular fltration rate lass than 50 mL/min/1.73 m2 by Cockcroft-Gualt
12. 12-lead electrocardiogram (ECG) showing the following: having a corrected QTc interval greater than 450 msec for males and greater than 470 msec for females or <340 msec (Fridericia's correction)
13. Clinically significant medical history of:
a. Cardiac diseases (e.g., myocardial infarctions, stroke, arrhythmia, heart failure, and coronary heart disease),
b. Autoimmune diseases (e.g. lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, moderate or severe psoriasis, thyroiditis), or
c. Malignancies within 3 years. Malignancy that has been successfully surgically resection and considered cured would not exclude the subject.
14. Treatment with an investigational drug, biological agent or device within 4 weeks or 5 half-lives prior to Screening, whichever is longer.
15. History of excess alcohol consumption within 1 year of Screening, defined as weekly intake of greater than or equal to 14 drinks per week (average of greater than or equal to 2 drinks per day)
16. History of drug abuse/addiction within 6 months of Screening (except cannabis)
17. Have any other conditions (medical. social. psychiatric. or other), which

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials